Having trouble accessing articles? Reset your cache.

Pradaxa dabigatran etexilate regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-0 that Boehringer's Pradaxa dabigatran should be approved for the reduction of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation (AF).

Read the full 326 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE